Format

Send to

Choose Destination
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):61-67. doi: 10.1158/1055-9965.EPI-16-0215. Epub 2016 Sep 1.

Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer.

Author information

1
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
2
Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
3
Department of Informatics, University of Oslo, Oslo, Norway.
4
KG Jebsen Center for Gynecologic Cancer Research, Haukeland University Hospital, Bergen, Norway.
5
Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
6
Department of Gynecology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
7
Department of Obstetrics and Gynecology, Halland's Hospital Varberg, Varberg, Sweden.
8
Department of Gynecology, St. Olav's Hospital, Trondheim, Norway.
9
Department of Gynecology, Oslo University Hospital, Ullevål, Oslo, Norway.
10
Department of Pathology, The Gade Institute, Haukeland University Hospital, Bergen, Norway.
11
Department of Obstetrics and Gynecology, Akershus University Hospital, Lørenskog, Norway.
12
University of Oslo, Oslo, Norway.
13
Department of Obstetrics and Gynecology, Haugesund Hospital, Haugesund, Norway.
14
Department of Obstetrics and Gynecology, Hospital of Vestfold, Tønsberg, Norway.
15
Department of Obstetrics and Gynecology, Førde Hospital, Førde, Norway.
16
Department of Obstetrics and Gynecology, Ålesund Hospital, Ålesund, Norway.
17
Department of Gynecologic Oncology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium.
18
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway. hdaniels@labmed.uio.no.
19
Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, United Kingdom.

Abstract

BACKGROUND:

Most endometrial carcinoma patients are diagnosed at an early stage with a good prognosis. However, a relatively low fraction with lethal disease constitutes a substantial number of patients due to the high incidence rate. Preoperative identification of patients with high risk and low risk for poor outcome is necessary to tailor treatment. Nucleotyping refers to characterization of cell nuclei by image cytometry, including the assessment of chromatin structure by nuclear texture analysis. This method is a strong prognostic marker in many cancers but has not been evaluated in preoperative curettage specimens from endometrial carcinoma.

METHODS:

The prognostic impact of changes in chromatin structure quantified with Nucleotyping was evaluated in preoperative curettage specimens from 791 endometrial carcinoma patients prospectively included in the MoMaTEC multicenter trial.

RESULTS:

Nucleotyping was an independent prognostic marker of disease-specific survival in preoperative curettage specimens among patients with Federation Internationale des Gynaecologistes et Obstetristes (FIGO) stage I-II disease (HR=2.9; 95% CI, 1.2-6.5; P = 0.013) and significantly associated with age, FIGO stage, histologic type, histologic grade, myometrial infiltration, lymph node status, curettage histology type, and DNA ploidy.

CONCLUSIONS:

Nucleotyping in preoperative curettage specimens is an independent prognostic marker for disease-specific survival, with potential to supplement existing parameters for risk stratification to tailor treatment.

IMPACT:

This is the first study to evaluate the prognostic impact of Nucleotyping in curettage specimens from endometrial carcinoma and shows that this may be a clinically useful prognostic marker in endometrial cancer. External validation is warranted. Cancer Epidemiol Biomarkers Prev; 26(1); 61-67. ©2016 AACR.

PMID:
27587790
DOI:
10.1158/1055-9965.EPI-16-0215
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center